These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12374277)

  • 1. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.
    Eiben GL; Velders MP; Kast WM
    Adv Cancer Res; 2002; 86():113-48. PubMed ID: 12374277
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
    Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
    Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
    J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
    Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunology of human papillomavirus infection in lower genital tract neoplasia.
    Man S; Fiander A
    Best Pract Res Clin Obstet Gynaecol; 2001 Oct; 15(5):701-14. PubMed ID: 11563868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical studies of human papilloma vaccines in cervical cancer.
    Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
    Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
    Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
    Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of human papillomavirus in carcinogenesis of cervical cancer and vaccination for HPV].
    Kariya M; Fujii S
    Uirusu; 2002 Dec; 52(2):287-93. PubMed ID: 12685321
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune evasion in human papillomavirus-associated cervical cancer.
    Tindle RW
    Nat Rev Cancer; 2002 Jan; 2(1):59-65. PubMed ID: 11902586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus in carcinogenesis of cervical cancer.
    de Silva NR; Mendis L; Perera N
    Ceylon Med J; 1999 Mar; 44(1):45-7. PubMed ID: 10643100
    [No Abstract]   [Full Text] [Related]  

  • 15. Origin and immunoescape of uterine cervical cancer.
    Van Hede D; Langers I; Delvenne P; Jacobs N
    Presse Med; 2014 Dec; 43(12 Pt 2):e413-21. PubMed ID: 25448124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women.
    Zehbe I; Mytilineos J; Wikström I; Henriksen R; Edler L; Tommasino M
    Hum Immunol; 2003 May; 64(5):538-42. PubMed ID: 12691704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity to oncogenic human papillomaviruses.
    Konya J; Dillner J
    Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.